Opens in a new tab or window During last year's respiratory virus season, newly approved vaccines for respiratory syncytial virus (RSV) were effective in preventing associated hospitalizations and ...

Opens in a new tab or window The CDC recommends a single dose of any FDA-approved respiratory syncytial virus (RSV) vaccine for all adults ages 75 years and older, as well as for 60- to 74-year ...

GSK on Wednesday said its vaccine sales would fall this year, after a weaker-than-expected performance for its respiratory ...

Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines, Moderna has done the ...

Oct. 18, 2024 – Older people who aren’t sure about whether to get the vaccine for respiratory syncytial virus (RSV) now have a new set of data to help them make up their minds. A large study ...

A global real-world study of the vaccine for respiratory syncytial virus (RSV) finds it offers folks aged 60 and over 80% protection against severe illness and/or hospitalization. With U.S ...

Pregnant women who get the RSV shot late in the pregnancy can pass along the antibodies to their infant. This is an option ...

Three months after revealing that its respiratory syncytial virus (RSV) preventive antibody clesrovimab had passed muster in a phase 2b/3 trial, Merck is putting numbers to the claim. Clesrovimab ...

The seasonal shot met its primary goal in the mid-to-late stage trial, reducing the incidence of RSV-associated, medically attended lower respiratory infections in healthy infants up to one year ...

Real-World Study Confirms RSV Vaccine's Protective Power for Seniors By Ernie Mundell HealthDay Reporter FRIDAY, Oct. 18, 2024 (HealthDay News) -- A global real-world study of the vaccine for ...